The patent application WO2011013785 describes delgocitinib, an orally administered JAK inhibitor. This compound is designed to treat autoimmune diseases by modulating the immune response.
What is Delgocitinib Used For?
Delgocitinib is investigated for the treatment of various autoimmune conditions. Its mechanism of action targets Janus kinases (JAKs), enzymes that play a crucial role in signaling pathways involved in inflammation and immune cell function. By inhibiting these kinases, delgocitinib aims to reduce the inflammatory processes characteristic of autoimmune diseases.
How Does Delgocitinib Work?
Delgocitinib functions as an inhibitor of Janus kinases (JAKs) [1]. Specifically, it targets JAKs, which are intracellular enzymes that transmit signals from cytokine and growth factor receptors on the cell surface to the nucleus. This signaling pathway is critical for the production and activity of various immune cells and inflammatory mediators. By blocking JAK activity, delgocitinib interrupts these pro-inflammatory cascades, thereby suppressing the aberrant immune responses seen in autoimmune disorders.
When Does the Patent for Delgocitinib Expire?
Information on the specific expiry dates for patents related to delgocitinib, including WO2011013785, is best obtained through specialized patent databases. DrugPatentWatch.com offers detailed insights into drug patents, including their status and expiration timelines [2].
Who is Developing Delgocitinib?
The development of delgocitinib is primarily associated with AnGes MG, Inc. and Mitsubishi Tanabe Pharma Corporation. They have been involved in its research and clinical evaluation for various indications.
What is the Difference Between Delgocitinib and Other JAK Inhibitors?
Delgocitinib is a selective JAK inhibitor, and its specific profile of JAK isoform inhibition can differentiate it from other JAK inhibitors on the market or in development. Different JAK inhibitors may have varying affinities for JAK1, JAK2, JAK3, and TYK2, leading to distinct efficacy and safety profiles. For example, some JAK inhibitors are approved for conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The precise clinical differentiation of delgocitinib relies on its performance in clinical trials for its target indications.
What are the Clinical Trial Results for Delgocitinib?
Clinical trials for delgocitinib have explored its efficacy and safety in treating conditions such as atopic dermatitis. Studies have reported on its ability to improve skin symptoms and quality of life for patients. Further details on specific trial outcomes can be found in published scientific literature and regulatory agency reports.
Can Biosimilars of Delgocitinib Be Developed?
The development of biosimilars for delgocitinib would be contingent on the expiry of its relevant patents and market exclusivity periods. Once these protections lapse, other companies may be able to develop and seek approval for biosimilar versions, provided they can demonstrate comparable quality, safety, and efficacy to the original biologic product.
What are the Risks and Side Effects Associated with Delgocitinib?
As with other JAK inhibitors, potential risks and side effects associated with delgocitinib may include an increased risk of infections, including serious infections, and potential effects on blood counts, lipid levels, and the risk of thrombosis. Patients and healthcare providers closely monitor for these during treatment. Specific side effect profiles are detailed in the drug's prescribing information and clinical trial data.
---
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/